<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83073">
  <stage>Registered</stage>
  <submitdate>13/08/2008</submitdate>
  <approvaldate>29/08/2008</approvaldate>
  <actrnumber>ACTRN12608000437369</actrnumber>
  <trial_identification>
    <studytitle>Applying Novel Biomarkers to Assess Cardiac Risk in Patients Undergoing Major Vascular Surgery: Defining Iron, Oxidative Stress, Inflammation, Matrix Metalloproteinases, Coagulation Factors, Lipidomics, Endothelial Dysfunction and Other Relevant Markers as Novel Risk Predictors</studytitle>
    <scientifictitle>Applying Novel Biomarkers to Assess Cardiac Risk in Patients Undergoing Major Vascular Surgery: Defining Iron, Oxidative Stress, Inflammation, Matrix Metalloproteinases, Coagulation Factors, Lipidomics, Endothelial Dysfunction and Other Relevant Markers as Novel Risk Predictors</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Coronary heart disease</healthcondition>
    <healthcondition>Peripheral vascular disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Obervational study. The study aims to observe whether a certain risk markers in blood correlate with the occurrence of cardiovascular events (CVE) following major vascular surgery. The intended duration of observation is at least 30 days following vascular surgery and up to 1 year per patient.</interventions>
    <comparator>Not applicable - Observational study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Peri-operative cardiovascular event (CVE) defined by a composite endpoint of peri-operative myocardial infarction (PMI) either ST-segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI); stroke; and/or cardiac death. It is anticipated that almost all PMIs will be of the NSTEMI type.</outcome>
      <timepoint>30 days post vascular surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PMI</outcome>
      <timepoint>30 days post vascular surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stroke</outcome>
      <timepoint>30 days post vascular surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac death</outcome>
      <timepoint>30 days post vascular surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients &gt;18 years of age. Vascular surgery either urgent, elective or semi-elective including: open repair of abdominal aortic aneurysm (AAA); supra-inguinal or infra-inguinal bypass or reconstructive surgery (e.g. aorto-bifemoral grafting).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>N/A</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unwilling to consent. Myocardial infarction &lt;6weeks. Percutaneous coronary intervention with bare stent &lt;6weeks; or drug-eluting stent &lt;12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>Heart Center
The Alfred Hospital, 
3rd Floor, W.S. Philip Block 
Commercial Road, Melbourne 3004, 
Victoria, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 5
20 Allara Street
Canberra
ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the project is to investigate the usefulness of novel markers (biomarkers) in predicting the risk of experiencing a CVE (defined as a composite of STEMI or NSTEMI, stroke, or death) during or after vascular surgery in patients with severe peripheral vascular disease (PVD) who require surgical correction or bypass. The risk of a CVE in this group of patients is typically about 20-25%. The prevalence of coronary artery disease in this select group of participants approaches 50% and increases with age. Current risk assessment methods, although useful, may not necessarily detect all at-risk patients, especially those without pre-existing symptoms of ischaemic heart disease such as angina or previous myocardial infarcts. This study will assess if newer methods can help detect at-risk patients who may not have symptoms of heart disease but who are still at risk of developing a CVE peri-operatively. 

Examples of novel biomarkers measured preoperatively include endothelial function testing by fingertip arterial tonometry, iron studies, myeloperoxidase, matrix metalloproteinase, and lipidomic profiling.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital 
Commercial Road
Melbourne 
Victoria 3004</ethicaddress>
      <ethicapprovaldate>17/06/2008</ethicapprovaldate>
      <hrec>Project 125/08</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr William Chan</name>
      <address>Heart Centre 
The Alfred Hospital, 3rd Floor, W.S. Philip Block 
Commercial Road, Melbourne 3004, Victoria</address>
      <phone>61-3-9076.3263</phone>
      <fax>61-3-9376.8438</fax>
      <email>w.chan2@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr William Chan</name>
      <address>Heart Centre 
The Alfred Hospital, 3rd Floor, W.S. Philip Block 
Commercial Road, Melbourne 3004, Victoria</address>
      <phone>61-3-9076.3263</phone>
      <fax>61-3-9376.8438</fax>
      <email>w.chan2@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr William Chan</name>
      <address>Heart Center
The Alfred Hospital, 3rd Floor, W.S. Philip Block 
Commercial Road, Melbourne 3004, Victoria</address>
      <phone>61-3-9076.3263</phone>
      <fax>61-3-9376.8438</fax>
      <email>w.chan2@alfred.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>